Who is sponsoring NCT00622362?

NCT00622362 is sponsored by Laboratorios Leti, S.L..

What drugs are being tested in NCT00622362?

Interventions in NCT00622362: DEPIGOID Dermatophagoides pteronyssinus, Polymerized TOL of Dermatophagoides pteronyssinus, Placebo Comparator.

What condition does NCT00622362 study?

NCT00622362 studies Allergic Asthma.

Is NCT00622362 still recruiting?

NCT00622362 is currently terminated. Last updated 6 March 2019.

Last reviewed 2019-03-06 · How we verify

NCT00622362

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Depigmented and Polymerised Allergenic Extract of Dermatophagoides Pteronyssinus as Antiasthmatic Treatment for Children With Slight Allergic Asthma to Mites

Terminated Phase 2 Last updated 6 March 2019

What this trial tests

Phase 2 trial testing DEPIGOID Dermatophagoides pteronyssinus in Allergic Asthma in 3 participants. Terminated before completion.

Timeline

1 January 2008

Primary endpoint
1 February 2009

1 February 2009

Quick facts

Lead sponsor	Laboratorios Leti, S.L.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	3
Start date	1 January 2008
Primary completion	1 February 2009
Estimated completion	1 February 2009
Sites	1 location across Spain

Drugs / interventions tested

DEPIGOID Dermatophagoides pteronyssinus — full drug profile →
Polymerized TOL of Dermatophagoides pteronyssinus — full drug profile →
Placebo Comparator

Conditions studied

Allergic Asthma — all drugs for Allergic Asthma →

Sponsor

Laboratorios Leti, S.L. — full company profile →

Who can join

Adults 5 to 14, any sex, with Allergic Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Symptom and medication scores
Time frame: 1 year per patient

Sponsor's own description

The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract Dermatophagoides pteronyssinus in children with allergic asthma due to this mite

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Allergic Asthma

Currently open trials in the same condition.

NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
NCT07342803 — Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients · Phase 2 · recruiting
NCT06438757 — Trial of JYB1904 in Patients With Allergic Asthma · Phase 2 · active not recruiting
NCT06771934 — Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00622362 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laboratorios Leti, S.L.
Last refreshed: 6 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00622362.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing